Preclinical study explores approved drug for ovarian cancer
August 01, 2024
August 01, 2024
ITHACA, New York, Aug. 1 -- Cornell University issued the following news:
An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.
The preclinical study, which combined the analysis of human ovarian tumors and animal models of the disease, was published July 29 in Cancer Discovery, a journal of the American Association for Cancer R . . .
An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.
The preclinical study, which combined the analysis of human ovarian tumors and animal models of the disease, was published July 29 in Cancer Discovery, a journal of the American Association for Cancer R . . .